Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + lenvatinib + gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of toripalimab (JS001), an anti-PD-1 monoclonal antibody; lenvatinib, a multi-kinase inhibitor; and the GEMOX chemotherapy regimen (gemcitabine and oxaliplatin). It is being investigated primarily for the treatment of advanced and unresectable intrahepatic cholangiocarcinoma (iCCA). Toripalimab works by blocking the PD-1 receptor on T-cells, enhancing the immune response against tumor cells. Lenvatinib inhibits multiple receptor tyrosine kinases, including VEGFR, FGFR, and PDGFR, to inhibit angiogenesis and tumor growth. Gemcitabine and oxaliplatin are cytotoxic agents that interfere with DNA synthesis and cause DNA damage, respectively. A Phase 2 study conducted at Shanghai Zhongshan Hospital (NCT03951597) demonstrated significant efficacy in patients with advanced iCCA, showing an objective response rate of 80%.
- Brand names
- LenvimaTuoyi
- Other names
- toripalimab + lenvatinib + GEMOXJS001 + lenvatinib + gemcitabine + oxaliplatin
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on toripalimab + lenvatinib + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + lenvatinib + gemcitabine + oxaliplatin.